BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

Free Newsletters
My Subscriptions

News by Subject
News by Disease
News by Date
Search News
Post Your News

Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Pharm Country
  Bio NC
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™


Company Profiles

Research Store

Research Events
Post an Event
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile


Portola Pharmaceuticals, Inc. 

270 East Grand Avenue

South San Francisco  California  94080  U.S.A.
Phone: 650-246-7000 Fax: 650-246-7376


View Clinical Trials from BioPharm Insight

Portola Pharmaceuticals, Inc. was founded in 2003 and is headquartered in South San Francisco, CA. We completed an initial public offering in May 2013 and are traded on the Nasdaq Stock Market under the symbol PTLA. We have approximately 80 employees. At Portola, our goal is to build an enduring biopharmaceutical company with compounds from our own research efforts that advance the care of patients in the areas of thrombosis (blood clots), other hematologic (blood) disorders and inflammation. Our development-stage portfolio includes three 100 percent-owned clinical-stage assets; betrixaban and andexanet alfa (PRT4445), which address significant unmet medical needs in the areas of thrombosis; and PRT2070, an orally available kinase inhibitor with unique pharmacologic properties that targets hematologic cancers.

 Key Statistics

Ownership: Private

Web Site: Portola Pharmaceuticals, Inc.

Start Up

 Company News
Portola Pharmaceuticals, Inc.'s ANNEXA™ Reverses Effect Of Anti-Clotting Drugs In Phase 3 Study 10/1/2014 9:04:32 AM
Portola Pharmaceuticals, Inc. To Present At The 2014 Morgan Stanley (MST) Global Healthcare Conference 9/2/2014 8:04:12 AM
Portola Pharmaceuticals, Inc. Reports Second Quarter Financial Results And Provides Corporate Update 8/6/2014 4:26:32 PM
Portola Pharmaceuticals, Inc. To Announce Second Quarter 2014 Financial Results And Host Conference Call On Wednesday, August 6, 2014 7/30/2014 4:06:39 PM
Portola Pharmaceuticals, Inc. Enters Into Clinical Collaboration Agreement With Daiichi Sankyo, Inc. (4568.t) For Phase 3 Studies Of Factor Xa Inhibitor Antidote, Andexanet Alfa, And Edoxaban 7/7/2014 12:35:34 PM
CMC Biologics Enters Into Commercial Supply Agreement With Portola Pharmaceuticals, Inc. For Manufacturing Of First-In-Class Factor Xa Inhibitor Antidote Andexanet Alfa 7/3/2014 6:29:56 AM
Portola Pharmaceuticals, Inc. To Present At The 2014 Wells Fargo Securities Healthcare Conference 6/13/2014 7:59:18 AM
Portola Pharmaceuticals, Inc. Announces Positive Phase 2 Data With FDA-Designated Breakthrough Therapy Andexanet Alfa and Enoxaparin 6/11/2014 6:34:15 AM
Portola Pharmaceuticals, Inc. Announces Two Presentations Of Data On Cerdulatinib, An Oral Dual Syk/JAK Inhibitor, At 2014 American Society of Clinical Oncology Annual Meeting 5/14/2014 3:04:06 PM
Portola Pharmaceuticals, Inc. Begins Enrollment In Phase 3 Study Of FDA-Designated Breakthrough Therapy Andexanet Alfa And Factor Xa Inhibitor XARELTO® 5/12/2014 10:01:50 AM